Tanvex BioPharma Competitors and Similar CompaniesClear all

Tanvex BioPharma's competitors and similar companies include OBI Pharma, Bora Pharmaceuticals and Lotus Pharmaceutical.

	Tanvex BioPharma Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs.	OBI Pharma OBI Pharma (台灣浩鼎) is a bio-pharma company focused on cancer therapeutics.	Bora Pharmaceuticals Bora Pharmaceuticals is a company that develops, manufactures, and sells branded, generic, and over the counter (OTC) healthcare products.	Lotus Pharmaceutical Lotus Pharmaceutical (美時化學製藥股份有限公司) is a company that develops, manufactures, and markets pharmaceutical products.
Founding Date	Founding Date 2013	Founding Date 2002	Founding Date 2007	Founding Date 1966
Type	Type Public	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development outsourcing pharma	Tags Healthcare biotech contractor drug development pharma
Locations	Locations Taipei, TW HQ New Taipei, TW Irvine, US San Diego, US San Diego, US	Locations TW HQ San Diego, US	Locations TW HQ Wilmington, US	Locations Taipei City, TW HQ Singapore, SG Ho Chi Minh City, VN
Employees	Employees 13628% decrease	Employees 124	Employees 6153% increase	Employees 66911% increase
Financial
Revenue (est.)	Revenue (est.) NT$61.4m (FY, 2023)	Revenue (est.) NT$41.5m (FY, 2023)	Revenue (est.) N/A	Revenue (est.) NT$18.6b (FY, 2024)
Cost of goods	Cost of goods NT$1.7m (FY, 2023)	Cost of goods NT$115m (FY, 2023)	Cost of goods N/A	Cost of goods NT$6.3b (FY, 2024)
Gross profit	Gross profit NT$61.6m (FY, 2023)	Gross profit (NT$63.8m) (FY, 2023)	Gross profit N/A	Gross profit NT$12.4b (FY, 2024)
Net income	Net income (NT$2.1b) (FY, 2023)	Net income (NT$1.3b) (FY, 2023)	Net income N/A	Net income NT$5.1b (FY, 2024)